|
|
Prepublished online as a Blood First Edition Paper on March 6, 2003; DOI 10.1182/blood-2002-11-3343.
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2003, Vol. 102, No. 1, pp. 43-52
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
Sonali M. Smith,
Michelle M. Le Beau,
Dezheng Huo,
Theodore Karrison,
Ronald M. Sobecks,
John Anastasi,
James W. Vardiman,
Janet D. Rowley, and
Richard A. Larson
From the Section of Hematology/Oncology, Department of Medicine; Section of Hematopathology, Department of Pathology; the Department of Health Studies; and the Cancer Research Center, University of Chicago, IL.
Therapy-related myelodysplasia and myeloid leukemia (t-MDS/t-AML) is a distinctive clinical syndrome occurring after exposure to chemotherapy (CT) or radiotherapy (RT). We report findings on 306 consecutive patients referred to our institution with morphologic review and cytogenetic analyses. Since 1972, 141 males and 165 females with a median age of 51 years (range, 3-83 years) at primary diagnosis and 58 years (range, 6-86 years) at secondary diagnosis were analyzed. Patients had been administered various cytotoxic agents, including alkylating agents (240 patients, 78%) and topoisomerase 2 inhibitors (115 patients, 39%). One hundred twenty-one (40%) had undergone CT alone, 43 (14%) had undergone RT alone, and 139 (45%) had undergone both modalities. At diagnosis of t-MDS/t-AML, 282 (92%) had clonal abnormalities involving chromosome 5 (n = 63), chromosome 7 (n = 85), chromosomes 5 and 7 (n = 66), recurring balanced rearrangements (n = 31), other clonal abnormalities (n = 39), or normal karyotype (n = 24). Abnormalities of chromosome 5, 7, or both accounted for 76% of all cases with an abnormal karyotype. Seventeen patients acquired t-MDS/t-AML after autologous stem cell transplantation, but no unique pattern of cytogenetic abnormalities was observed. Shorter latency was observed for patients with balanced rearrangements (median, 28 vs 67 months; P < .0001). Patients with acute leukemia were more likely to have balanced rearrangement than those with myelodysplasia (28% vs 4%; P < .0001). Median survival time after diagnosis of t-MDS/t-AML was 8 months; survival at 5 years was less than 10%. These data confirm and extend previous associations between clinical, morphologic, and cytogenetic findings in t-MDS/t-AML. (Blood. 2003;102:43-52)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Secondary leukemia or unfavorable leukemia?
- Jacob M. Rowe
Blood 2003 102: 1.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. A. Lichtman
Is There an Entity of Chemically Induced BCR-ABL-Positive Chronic Myelogenous Leukemia?
Oncologist,
June 1, 2008;
13(6):
645 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Shivakumar, W. Tan, G. E. Wilding, E. S. Wang, and M. Wetzler
Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases
Ann. Onc.,
May 7, 2008;
(2008)
mdn182v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Lichtman
Battling the Hematological Malignancies: The 200 Years' War
Oncologist,
February 1, 2008;
13(2):
126 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso
Therapy-related leukemia and myelodysplasia: susceptibility and incidence
Haematologica,
October 1, 2007;
92(10):
1389 - 1398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Czuczman, C. Emmanouilides, M. Darif, T. E. Witzig, L. I. Gordon, S. Revell, K. Vo, and A. Molina
Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy
J. Clin. Oncol.,
September 20, 2007;
25(27):
4285 - 4292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Chang, B. E. Storer, B. L. Scott, E. M. Bryant, H. M. Shulman, M. E. Flowers, B. M. Sandmaier, R. P. Witherspoon, R. A. Nash, J. E. Sanders, et al.
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
Blood,
August 15, 2007;
110(4):
1379 - 1387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Joslin, A. A. Fernald, T. R. Tennant, E. M. Davis, S. C. Kogan, J. Anastasi, J. D. Crispino, and M. M. Le Beau
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders
Blood,
July 15, 2007;
110(2):
719 - 726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al.
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
Blood,
April 1, 2007;
109(7):
2781 - 2790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Agrawal, M. Unterberg, S. Koschmieder, U. zur Stadt, U. Brunnberg, W. Verbeek, T. Buchner, W. E. Berdel, H. Serve, and C. Muller-Tidow
DNA Methylation of Tumor Suppressor Genes in Clinical Remission Predicts the Relapse Risk in Acute Myeloid Leukemia
Cancer Res.,
February 1, 2007;
67(3):
1370 - 1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen
Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
392 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Larson
Etiology and Management of Therapy-Related Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
453 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shannon and L. R. Silverman
Myelodysplastic syndrome and overlap syndromes
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
228 - 242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell
Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
J. Clin. Oncol.,
August 1, 2006;
24(22):
3604 - 3610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Noronha, N. Berliner, K. K. Ballen, J. Lacy, J. Kracher, J. Baehring, and J. W. Henson
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature
Neuro-oncol,
July 1, 2006;
8(3):
280 - 283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Geiger, D. Schleimer, K. J. Nattamai, S. R. Dannenmann, S. M. Davies, and B. D. Weiss
Mutagenic potential of temozolomide in bone marrow cells in vivo.
Blood,
April 1, 2006;
107(7):
3010 - 3011.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Qian, L. Mao, and M. Lebeau
Genetic Pathways in Therapy-Related Leukemia: FHL2 Cooperates with del(5q).
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
648 - 648.
[Abstract]
|
|
|
|
|
|
|
S. E. Craven, D. French, W. Ye, F. de Sauvage, and A. Rosenthal
Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome
Blood,
May 1, 2005;
105(9):
3528 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Mistry, C. A. Felix, R. J. Whitmarsh, A. Mason, A. Reiter, B. Cassinat, A. Parry, C. Walz, J. L. Wiemels, M. R. Segal, et al.
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
N. Engl. J. Med.,
April 14, 2005;
352(15):
1529 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pagano, A. Pulsoni, M. Vignetti, M. E. Tosti, P. Falcucci, P. Fazi, L. Fianchi, A. Levis, A. Bosi, E. Angelucci, et al.
Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials
Ann. Onc.,
February 1, 2005;
16(2):
228 - 233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood,
February 1, 2005;
105(3):
959 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tichelli and G. Socie
Considerations for Adult Cancer Survivors
Hematology,
January 1, 2005;
2005(1):
516 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Christiansen, M. K. Andersen, and J. Pedersen-Bjergaard
Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation
Blood,
September 1, 2004;
104(5):
1474 - 1481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Larson
Therapy-related myeloid leukemia: stochastic or idiosyncratic?
Blood,
August 1, 2004;
104(3):
602 - 603.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Kern, T. Haferlach, S. Schnittger, W. Hiddemann, and C. Schoch
Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of Karyotype
J. Clin. Oncol.,
June 15, 2004;
22(12):
2510 - 2511.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Voso, A. Scardocci, F. Guidi, G. Zini, A. Di Mario, L. Pagano, S. Hohaus, and G. Leone
Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes
Blood,
January 15, 2004;
103(2):
698 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, J. M. Bennett, K. J. Kopecky, T. Buchner, C. L. Willman, E. H. Estey, C. A. Schiffer, H. Doehner, M. S. Tallman, T. A. Lister, et al.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
J. Clin. Oncol.,
December 15, 2003;
21(24):
4642 - 4649.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
